Publications

McGrath LJ, Nielson C, Saul B, Breskin A, Yu Y, Nicolaisen SK, … Kelsh M, et al. 2021. Lessons learned using real-world data to emulate randomized trials: A case study of treatment effectiveness for newly diagnosed immune thrombocytopenia. Clin Pharmacol Ther 110(6):1570–1578; doi: 10.1002/cpt.2399.

McGrath LJ, Nielson C, Saul B, Breskin A, Yu Y, Nicolaisen SK, … Kelsh M, et al. 2021. Lessons learned using real-world data to emulate randomized trials: A case study of treatment effectiveness for newly diagnosed immune thrombocytopenia. Clin Pharmacol Ther 110(6):1570–1578; doi: 10.1002/cpt.2399. PMID: 34416023.

Hathway J, Miller-Wilson L, Sharma A, Jensen I, Yao W, Raza S, et al. 2021. The impact of increasing multitarget stool DNA use among colorectal cancer screeners in a self-insured US employer population. J Mark Access Health Policy, 9(1):1948670; doi: 10.1080/20016689.2021.1948670.

Haddadin Z, Rankin DA, Lipworth L, Suh M, McHenry R, Blozinski A, Salib George S, Fernandez KN, Varjabedian R, Spieker AJ, Shepard DS, Halasa NB. 2021. Respiratory virus surveillance in infants across different clinical settings. J Pediat 234:164-171; doi: 10.1016/j.jpeds.2021.03.036.

Haddadin Z, Rankin DA, Lipworth L, Suh M, McHenry R, Blozinski A, Salib George S, Fernandez KN, Varjabedian R, Spieker AJ, Shepard DS, Halasa NB. 2021. Respiratory virus surveillance in infants across different clinical settings. J Pediat 234(July):p164-p171; doi: 10.1016/j.jpeds.2021.03.036.

Vágó EK, Nicholson G, Horváth-Puhó E. Hooda N, Fryzek JP, Su J. 2021. Healthcare resource utilization among patients with cold agglutinin disease in Denmark. Curr Med Res Opin 37(10):1829-1835; doi: 10.1080/03007995.2021.1960494.

Mayne TJ, Nordyke RJ, Schold JD, Weir MR, Mohan S. 2021. Defining a minimal clinically meaningful difference in 12-month estimated glomerular filtration rate for clinical trials in deceased donor kidney transplantation. Clin Transplant 35(7):e14326; doi: 10.1111/ctr.14326. PMID: 33896052.

Dean R, Jensen IS, Cyr PL, Miller B, Maru B, Sproule DM, Feltner DE, et al. 2021. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Pol 9(1):1889841; doi: 10.1080/20016689.2021.1889841.

Proctor DM, Bhat V, Suh M, Reichert H, Jiang X, Thompson CM. 2021. Inhalation cancer risk assessment for environmental exposure to hexavalent chromium: Comparison of margin-of-exposure and linear extrapolation approaches. Regul Toxicol Pharmacol 124(August):104969; doi: 10.1016/j.yrtph.2021.104969. PMID: 34089813.

Nielson CM, Bylsma LC, Fryzek JP, Saad HA, Crawford J. 2021. Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: A systematic review and meta-analysis. Oncologist 26(9):e1609–e1618; doi: 10.1002/onco.13822. PMID: 33973301.